Clinical Trials Search
Clinical Trial 18741
Interventions:Adriamycin (doxorubicin); Not Applicable; doxorubicin
Study Type: Treatment
Phase of Study: Phase III
- Ghassan El-Haddad
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A Phase 3 Randomized Multicenter Trial to Compare Hepatic Progression-Free Survival Following Bland Embolization, Lipiodol Chemoembolization, and Drug-Eluting Bead Chemoembolization of Neuroendocrine Liver Metastases
The purpose of this study is 1) to determine if one or more of three techniques provide longer-lasting control of tumors in the liver, and 2) to see if outcomes for participants treated with the three techniques show that there are differences in quality of life, side effects, or safety.
To estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization.